Advertisement

Comparison of the Efficacy and Safety of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stents in Patients With ST-Elevation Myocardial Infarction

Published:September 28, 2009DOI:https://doi.org/10.1016/j.amjcard.2009.06.059
      Drug-eluting stents (DESs) are increasingly used for treatment of acute ST-segment elevation myocardial infarction (STEMI), but there are few comparisons of outcomes of various types of DES. We compared the efficacy and safety of zotarolimus-eluting stents (ZESs), sirolimus-eluting stents (SESs), and paclitaxel-eluting stents (PESs) in primary intervention for STEMI. This multicenter, prospectively randomized ZEST-AMI trial included 328 patients at 12 medical centers who were randomly assigned to ZES (n = 108), SES (n = 110), or PES (n = 110) deployment. The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months. Secondary end points included the individual components of the primary end point, late loss, angiographic restenosis, and stent thrombosis. Baseline clinical and angiographic characteristics were well matched. In-segment late loss (0.28 ± 0.42 vs 0.46 ± 0.48 vs 0.47 ± 0.50 mm, respectively, p = 0.029) and restenosis rate (2.7% vs 15.9% vs 12.3%, respectively, p = 0.027) at 8 months were lowest in the SES group compared to the ZES and PES groups. At 12 months, cumulative incidence rates of primary end points in the ZES, SES, and PES groups were 11.3%, 8.2%, and 8.2%, respectively (p = 0.834). There were 2 acute (in the SES group) and 5 subacute (2 in the SES group and 3 in the PES group) stent thromboses. Incidence of death, recurrent MI, or ischemia-driven target vessel revascularization did not differ among the 3 groups. In conclusion, despite the difference in restenosis rate, the efficacy and safety of the 3 different DESs showed similar, acceptable results in the treatment of STEMI.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Keeley E.C.
        • Boura J.A.
        • Grines C.L.
        Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.
        Lancet. 2003; 361: 13-20
        • Zhu M.M.
        • Feit A.
        • Chadow H.
        • Alam M.
        • Kwan T.
        • Clark L.T.
        Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials.
        Am J Cardiol. 2001; 88: 297-301
        • Moses J.W.
        • Leon M.B.
        • Popma J.J.
        • Fitzgerald P.J.
        • Holmes D.R.
        • O'Shaughnessy C.
        • Caputo R.P.
        • Kereiakes D.J.
        • Williams D.O.
        • Teirstein P.S.
        • Jaeger J.L.
        • Kuntz R.E.
        • SIRIUS Investigators
        Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
        N Engl J Med. 2003; 349: 1315-1323
        • Stone G.W.
        • Moses J.W.
        • Ellis S.G.
        • Schofer J.
        • Dawkins K.D.
        • Morice M.C.
        • Colombo A.
        • Schampaert E.
        • Grube E.
        • Kirtane A.J.
        • Cutlip D.E.
        • Fahy M.
        • Pocock S.J.
        • Mehran R.
        • Leon M.B.
        Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
        N Engl J Med. 2007; 356: 998-1008
        • Kastrati A.
        • Mehilli J.
        • Pache J.
        • Kaiser C.
        • Valgimigli M.
        • Kelbaek H.
        • Menichelli M.
        • Sabaté M.
        • Suttorp M.J.
        • Baumgart D.
        • Seyfarth M.
        • Pfisterer M.E.
        • Schömig A.
        Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.
        N Engl J Med. 2007; 356: 1030-1039
        • Tu J.V.
        • Bowen J.
        • Chiu M.
        • Ko D.T.
        • Austin P.C.
        • He Y.
        • Hopkins R.
        • Tarride J.E.
        • Blackhouse G.
        • Lazzam C.
        • Cohen E.A.
        • Goeree R.
        Effectiveness and safety of drug-eluting stents in Ontario.
        N Engl J Med. 2007; 357: 1393-1402
        • Beohar N.
        • Davidson C.J.
        • Kip K.E.
        • Goodreau L.
        • Vlachos H.A.
        • Meyers S.N.
        • Benzuly K.H.
        • Flaherty J.D.
        • Ricciardi M.J.
        • Bennett C.L.
        • Williams D.O.
        Outcomes and complications associated with off-label and untested use of drug-eluting stents.
        JAMA. 2007; 297: 1992-2000
        • Grines C.L.
        Off-label use of drug-eluting stents putting it in perspective.
        J Am Coll Cardiol. 2008; 51: 615-617
        • Daemen J.
        • Tanimoto S.
        • García-García H.M.
        • Kukreja N.
        • van de Sande M.
        • Sianos G.
        • de Jaegere P.P.
        • van Domburg R.T.
        • Serruys P.W.
        Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH registries).
        Am J Cardiol. 2007; 99: 1027-1032
        • Steg G.
        DES fall from GRACE in STEMI: patients face more than fourfold higher risk of death than bare-metal stent treated patients.
        (Heart-wire) (Accessed September 4, 2007)
        • Laarman G.J.
        • Suttorp M.J.
        • Dirksen M.T.
        • van Heerebeek L.
        • Kiemeneij F.
        • Slagboom T.
        • van der Wieken L.R.
        • Tijssen J.G.P.
        • Rensing B.J.
        • Patterson M.
        Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention.
        N Engl J Med. 2006; 355: 1105-1113
        • Spaulding C.
        • Henry P.
        • Teiger E.
        • Beatt K.
        • Bramucci E.
        • Carrie D.
        • Slama M.S.
        • Merkely B.
        • Erglis A.
        • Margheri M.
        • Varenne O.
        • Cebrian A.
        • Stoll H.P.
        • Snead D.B.
        • Bode C.
        • TYPHOON Investigators
        Sirolimus-eluting versus uncoated stents in acute myocardial infarction.
        N Engl J Med. 2006; 355: 1093-1104
        • Menichelli M.
        • Parma A.
        • Pucci E.
        • Fiorilli R.
        • De Felice F.
        • Nazzaro M.
        • Giulivi A.
        • Alborino D.
        • Azzellino A.
        • Violini R.
        Randomized trial of sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction (SESAMI).
        J Am Coll Cardiol. 2007; 49: 1924-1930
        • Valgimigli M.
        • Percoco G.
        • Malagutti P.
        • Campo G.
        • Ferrari F.
        • Barbieri D.
        • Cicchitelli G.
        • McFadden E.P.
        • Merlini F.
        • Ansani L.
        • Guardigli G.
        • Bettini A.
        • Parrinello G.
        • Boersma E.
        • Ferrari R.
        Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
        JAMA. 2005; 293: 2109-2117
        • Valgimigli M.
        • Campo G.
        • Percoco G.
        • Bolognese L.
        • Vassanelli C.
        • Colangelo S.
        • de Cesare N.
        • Rodriguez A.E.
        • Ferrario M.
        • Moreno R.
        • Piva T.
        • Sheiban I.
        • Pasquetto G.
        • Prati F.
        • Nazzaro M.S.
        • Parrinello G.
        • Ferrari R.
        Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators.
        JAMA. 2008; 299: 1788-1799
        • Hannan E.L.
        • Racz M.
        • Walford G.
        • Holmes D.R.
        • Jones R.H.
        • Sharma S.
        • Katz S.
        • King III, S.B.
        Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction.
        JACC Cardiovasc Interv. 2008; 1: 129-135
        • Pasceri V.
        • Patti G.
        • Speciale G.
        • Pristipino C.
        • Richichi G.
        • Di Sciascio G.
        Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction.
        Am Heart J. 2007; 153: 749-754
        • Kastrati A.
        • Dibra A.
        • Spaulding C.
        • Laarman G.J.
        • Menichelli M.
        • Valgimigli M.
        • Lorenzo E.D.
        • Kaiser C.
        • Tierala I.
        • Mehilli J.
        • Seyfarth M.
        • Varenne O.
        • Dirksen M.T.
        • Percoco G.
        • Varricchio A.
        • Pittl U.
        • Syvänne M.
        • Suttorp M.J.
        • Violini R.
        • Schömig A.
        Meta-analysis of randomized trials on drug-eluting stents versus bare-metal stents in patients with acute myocardial infarction.
        Eur Heart J. 2007; 28: 2706-2713
        • Percoco G.
        • Manari A.
        • Guastaroba P.
        • Campo G.
        • Guiducci V.
        • Aurier E.
        • Sangiorgio P.
        • Passerini F.
        • Geraci G.
        • Piovaccari G.
        • Naldi M.
        • Saia F.
        • Marzocchi A.
        Safety and long-term efficacy of sirolimus eluting stent in ST-elevation acute myocardial infarction: the REAL (Registro REgionale AngiopLastiche Emilia-Romagna) registry.
        Cardiovasc Drugs Ther. 2006; 20: 63-68
        • Mauri L.
        • Silbaugh T.S.
        • Garg P.
        • Wolf R.E.
        • Zelevinsky K.
        • Lovett A.
        • Varma M.R.
        • Zhou Z.
        • Normand S.L.T.
        Drug-eluting or bare-metal stents for acute myocardial infarction.
        N Engl J Med. 2008; 359: 1330-1342
        • Shishehbor M.H.
        • Amini R.
        • Oliveria L.P.J.
        • Singh I.M.
        • Kelly P.
        • Bhatt D.L.
        • Kapadia S.R.
        • Ellis S.G.
        • Whitlow P.L.
        • Brener S.J.
        Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction.
        JACC Cardiovasc Interv. 2008; 1: 227-232
        • Kandzari D.E.
        • Leon M.B.
        Overview of pharmacology and clinical trials program with the zotarolimus-eluting Endeavor stent.
        J Interv Cardiol. 2006; 19: 405-413
        • Gershlick A.
        • Kandzari D.E.
        • Leon M.B.
        • Wijns W.
        • Meredith I.T.
        • Fajadet J.
        • Popma J.J.
        • Fitzgerald P.J.
        • Kuntz R.E.
        • ENDEAVOR Investigators
        Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients.
        Am J Cardiol. 2007; 100: S45-S55
        • Kandzari D.E.
        • Leon M.B.
        • Popma J.J.
        • Fitzgerald P.J.
        • O'Shaughnessy C.
        • Ball M.W.
        • Turco M.
        • Applegate R.J.
        • Gurbel P.A.
        • Midei M.G.
        • Badre S.S.
        • Mauri L.
        • Thompson K.P.
        • LeNarz L.A.
        • Kuntz R.E.
        • ENDEAVOR III Investigators
        Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
        J Am Coll Cardiol. 2006; 48: 2440-2447
        • Meredith I.T.
        • Ormiston J.
        • Whitbourn R.
        • Kay I.P.
        • Muller D.
        • Popma J.J.
        • Cutlip D.E.
        • Fitzgerald P.J.
        • ENDEAVOR I Investigators
        Four-year clinical follow-up after implantation of the Endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study.
        Am J Cardiol. 2007; 100: 56M-61M
        • Lee J.H.
        • Kim H.S.
        • Lee S.W.
        • Park J.H.
        • Choi S.W.
        • Jeong J.O.
        • Cho Y.
        • Lee N.
        • Rhee K.S.
        • Ko J.K.
        • Seong I.W.
        Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: PROSIT trial.
        Catheter Cardiovasc Interv. 2008; 72: 25-32
        • Whelan D.M.
        • van der Giessen W.J.
        • Krabbendam S.C.
        • van Vliet E.A.
        • Verdouw P.D.
        • Serruys P.W.
        • van Beusekom H.M.
        Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries.
        Heart. 2000; 83: 338-345
        • Nakazawa G.
        • Finn A.V.
        • John M.C.
        • Kolodgie F.D.
        • Virmani R.
        The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents.
        Am J Cardiol. 2007; 100: 36M-44M
        • Ellis S.G.
        • Popma J.J.
        • Lasala J.M.
        • Koglin J.J.
        • Cox D.A.
        • Hermiller J.
        • O'Shaughnessy C.
        • Mann J.T.
        • Turco M.
        • Caputo R.
        • Bergin P.
        • Greenberg J.
        • Stone G.W.
        Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial.
        J Am Coll Cardiol. 2005; 45: 1193-1200
        • Luscher T.F.
        • Steffel J.
        • Eberli F.R.
        • Joner M.
        • Nakazawa G.
        • Tanner F.C.
        • Virmani R.
        Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications.
        Circulation. 2007; 115: 1051-1058